BIOSECURE Act Reshapes Pharmaceutical Supply Chain: New Cold Chain Challenges Under the Nearshoring Wave

Event Overview

In 2025, the U.S. Congress passed the BIOSECURE Act, incorporating it into the National Defense Authorization Act, formally initiating federal procurement restrictions on specific foreign biotechnology suppliers. The Act directly targets several companies, including China's BGI Genomics and WuXi AppTec, requiring U.S. government agencies and federally funded medical programs to phase out the use of their products and services by 2032. Although the core objective of the Act is to safeguard national security, its ripple effects have spread across the entire pharmaceutical supply chain—multinational drug companies are being forced to reassess long-reliance on overseas manufacturing partners and accelerate the shift from "low-cost concentration" to "diversified nearshoring."

Supply Chain Background

The global pharmaceutical supply chain has long been characterized by high geographical concentration. Approximately 80% of active pharmaceutical ingredient (API) production capacity is concentrated in China and India, while the manufacturing of high-end products such as biologics and vaccines relies on a few contract development and manufacturing organizations (CDMOs) in Europe, the Americas, and Asia. Long-distance, multi-node transportation networks expose temperature-sensitive drugs (e.g., monoclonal antibodies, mRNA vaccines, cell and gene therapy products) to significant temperature control risks. According to industry research, biologics now account for over 30% of the global pharmaceutical market, with more than 60% of these products requiring cold chain transportation. Supply chain disruptions or temperature excursions could result in tens of millions of dollars in product losses and jeopardize patient lives.

Corporate Decision-Making Logic

Facing compliance pressure from the BIOSECURE Act, pharmaceutical companies must weigh three trade-offs:

• Procurement Cost: Nearshoring typically increases unit manufacturing costs but shortens lead times and reduces tariff and exchange rate risks.
• Supply Chain Resilience: The single-source model is criticized as "fragile"; diversification increases the number of nodes but reduces the probability of single-point failure.
• Delivery Reliability: New suppliers require process validation and regulatory approval, with certification cycles of 12–24 months, during which inventory buffers must be maintained.

Therefore, companies generally adopt a "China+1" or "friend-shoring" strategy—retaining some Chinese capacity while establishing backup or parallel capacity in Mexico, Ireland, South Korea, or Eastern Europe. For instance, some large pharmaceutical companies have signed long-term agreements with CDMOs in Ireland or Puerto Rico to produce key biologics.

Supply Chain Impact

Supplier Management

An increase in the number of suppliers leads to higher audit and compliance costs. Drug companies need to assess new partners' GMP compliance, ESG performance, and geopolitical risks. It is estimated that within three years, the number of qualified suppliers for each core product will increase from 2–3 to 4–5.

Inventory Levels

To cope with extended transit times and port congestion, companies generally raise safety stock levels. In particular, the demand for ambient and cold storage space for temperature-controlled drugs increases by 20%–30%.

Transportation Efficiency

New trade routes (e.g., Southeast Asia → Mexico, Ireland → U.S. East Coast) still have underdeveloped cold chain infrastructure.Transport Efficiency

Cold chain infrastructure for new trade routes (e.g., Southeast Asia → Mexico, Ireland → U.S. East Coast) remains underdeveloped. Increasing intermodal transfer points (air + truck) raise the risk of temperature deviations. Enterprises need more advanced passive cold chain packaging (phase change materials) and real-time monitoring systems.

Digitalization

Real-time temperature tracking, blockchain traceability, and predictive risk platforms become standard. According to supply chain technology vendors, global pharmaceutical cold chain digital investment will grow at over 15% annually from 2024 to 2027.

Risk Exposure

While geographic dispersion reduces the impact of "black swan" events (e.g., a single factory fire or political conflict), systemic risks (e.g., global chip shortages affecting cold storage controllers) are still rising. Companies are beginning to build "resilience indexes" to evaluate each node.

Regional Impact

• Asia: Chinese API exports face short-term pressure, but large CXOs are expanding capacity in Southeast Asia (Singapore, Malaysia) to serve multinational clients. India benefits from generic drug formulations, but high-end biologics manufacturing still relies on technology transfer from Europe and the U.S.
• Europe: Ireland, with its tax advantages and GMP recognition, has become a core hub for biologics manufacturing; Switzerland and Germany maintain their lead in high-end CDMO. Post-Brexit mutual recognition issues remain unresolved, leading some companies to add nodes within the EU.
• North America: Mexico's nearshoring capacity is surging, but cold chain logistics corridors (e.g., low-temperature transfer stations at the U.S.-Mexico border) still need upgrades. The U.S. is restarting API production under the Inflation Reduction Act, but full rebuilding will take 5–10 years.
• Middle East & Latin America: Saudi Arabia and the UAE are using sovereign funds to invest in localized mRNA vaccine manufacturing; Brazil, as a South American hub, is poised to take on biosimilar production, but the cold chain infrastructure gap remains significant.
• Africa: Severe cold chain gaps make high-end manufacturing unlikely in the short term, but the region is becoming a pilot area for international organizations (GAVI, WHO) to promote local vaccine filling.

Future Trends (2026–2030)

1. Resilience-First Paradigm: Supply chain decision metrics will shift from "lowest landed cost" to "resilience-weighted cost," with temperature-controlled logistics costs expected to rise from 5% to 8%–10% of pharmaceutical costs. 2. Digital Twins: Use simulation modeling to optimize the balance between inventory and service levels in nearshoring scenarios. 3. ESG Transparency: Supplier carbon footprints and labor conditions become entry requirements, with blockchain traceability systems gradually embedded in regulatory compliance. 4. Ultra-Low Temperature Cold Chain Innovation: Gene therapies (requiring -70°C to -196°C) drive new-generation passive UHL packaging and liquid nitrogen dry shipping solutions. 5. Collaborative Alliances: Pharmaceutical companies, logistics integrators (e.g., DHL, UPS), and technology platforms form "cold chain alliances" to share capacity and data.

Key Conclusions## Key Conclusions

The BIOSECURE Act accelerates the transformation of the pharmaceutical supply chain from "efficiency-first" to "resilience-first," but in the short term, it increases operational complexity and temperature control risks. Companies need to find a balance between diversified deployment and digital monitoring, while establishing transparent coordination mechanisms with regulators and logistics partners. Over the next five years, cold chain management capabilities will directly determine the competitive position of pharmaceutical companies in the global market.